title: Will CSF biomarkers guide future therapeutic decisions in multiple sclerosis?
authors: From The Neuroimmunological Diseases Unit (B.B.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and the Department of Biostatistics and Computational Biology (M.P.M.), University of Rochester Medical Center, NY. bibi.bielekova@nih.gov.
authors: Bibiana
authors: B
authors: Bielekova
authors: From The Neuroimmunological Diseases Unit (B.B.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and the Department of Biostatistics and Computational Biology (M.P.M.), University of Rochester Medical Center, NY.
authors: Michael P
authors: MP
authors: McDermott
mesh_terms: D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007382:Intermediate Filaments; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000134:cerebrospinal fluid* / Q000188:drug therapy*; D009454:Neurofibrils; D011409:Propylene Glycols / Q000494:pharmacology*; D013110:Sphingosine / Q000031:analogs & derivatives*
chemical_list: D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D013110:Sphingosine